Literature DB >> 19517111

[Uterine sarcoma treatment].

G Köhler1.   

Abstract

There are many common features between uterine sarcomas - leiomyosarcoma, endometrial stromal sarcoma, undifferentiated endometrial sarcoma and adenosarcoma -with regards to course, therapy and follow-up, such as post-menopausal bleeding or additional premenopausal bleeding, as well as rapid growth. There is a new staging system according to FIGO and new therapy recommendations according to NCCN. Prior to therapy, imaging staging of the pelvis, abdomen and chest should be carried out due to the frequency with which metastases are found at the time of diagnosis. In the case of disease spread in uterine sarcomas and malignant mixed tumors, good supportive therapy is a possible therapy option instead of chemo- or radiotherapy. The approach - observation, surgery, lymphonodectomy, mono- or polychemotherapy, radiotherapy, hormone therapy - is chosen according to the extent of spread and the resection status. Neoadjuvant therapies are not as yet established.

Entities:  

Mesh:

Year:  2009        PMID: 19517111     DOI: 10.1007/s00292-009-1150-3

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  82 in total

1.  Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases.

Authors:  W Y Kim; J-W Lee; C H Choi; H Kang; T-J Kim; B-G Kim; J-H Lee; D-S Bae
Journal:  Int J Gynecol Cancer       Date:  2007-12-27       Impact factor: 3.437

2.  Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.

Authors:  T C Krivak; J D Seidman; J W McBroom; P J MacKoul; L M Aye; G S Rose
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

3.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

4.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

Review 5.  Uterine leiomyosarcomas coexistent with cellular and atypical leiomyomata in a young woman during the treatment with luteinizing hormone-releasing hormone agonist.

Authors:  W Y Lee; C C Tzeng; C Y Chou
Journal:  Gynecol Oncol       Date:  1994-01       Impact factor: 5.482

6.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

Authors:  Katherine Y Look; Alan Sandler; John A Blessing; Joseph A Lucci; Peter G Rose
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

7.  Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.

Authors:  B A Goff; L W Rice; D Fleischhacker; H G Muntz; S S Falkenberry; N Nikrui; A F Fuller
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

8.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

Authors:  Martee L Hensley; Nicole Ishill; Robert Soslow; Joseph Larkin; Nadeem Abu-Rustum; Paul Sabbatini; Jason Konner; William Tew; David Spriggs; Carol A Aghajanian
Journal:  Gynecol Oncol       Date:  2009-01-09       Impact factor: 5.482

9.  Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

Authors:  Daniel S Kapp; Jacob Y Shin; John K Chan
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

Review 10.  Hormonal therapy of endometrial stromal sarcoma.

Authors:  Olaf Reich; Sigrid Regauer
Journal:  Curr Opin Oncol       Date:  2007-07       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.